我院2007～2009年静脉用抗肿瘤药应用分析

Utilization of Antineoplastics for Intravenous Use in Our Hospital from 2007 to 2009

目的:评价我院静脉用抗肿瘤药的应用情况,为临床用药和药物经济学研究提供参考。方法:采用金额排序法和用药频度(DDDs)分析法对我院2007～2009年静脉用抗肿瘤药的应用情况进行统计、分析。结果:近3年来我院静脉用抗肿瘤药用量及销售金额呈快速上升趋势,其DDDs与整体销售金额排序差异较大,如多西他赛注射液等。植物来源静脉用抗肿瘤药所占比例较大,占销售金额排序前10位中的50%。结论:我院静脉用抗肿瘤药品种基本保持稳定,在临床应用中发展迅速,并向价格更合理、疗效更确切、不良反应更小的趋势发展。

OBJECTIVE：To evaluated the utilization of antineoplastics for intravenous use in our hospital and to provide references for clinical medication and pharmacoeconomic research. METHODS：The utilization of antineoplastics in our hospital from 2007 to 2009 was statistically analyzed in respect of consumption sum and DDDs. RESULTS：Amount and consumption sum of antineoplastics in our hospital increased rapidly in recent 3 years. The DDDs of drug were markedly different from their consumption sum rank,for example Docetaxel injection. Antineoplastics for intravenous use sourcing from plants took up big proportion of antineoplastics and they accounted for 50% of the top 10 antineoplastics in the list of consumption sum. CONCLUSION：The antineoplastics for intravenous use in our hospital basically remain stable in category and develop rapidly in recent years,which focus on reasonable price,exact therapeutic effect and less adverse reaction.